Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

German P, Warren D, West S, Hui J, Kearney BP.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):323-9. doi: 10.1097/QAI.0b013e3181eb376b.

PMID:
20683270
[PubMed - indexed for MEDLINE]
2.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team.

Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.

PMID:
22748590
[PubMed - indexed for MEDLINE]
3.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
[PubMed - indexed for MEDLINE]
4.

Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

Lampiris HW.

Expert Rev Anti Infect Ther. 2012 Jan;10(1):13-20. doi: 10.1586/eri.11.157. Review.

PMID:
22149610
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.

Ramanathan S, Shen G, Cheng A, Kearney BP.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):274-9.

PMID:
17414929
[PubMed - indexed for MEDLINE]
6.

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.

Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.

HIV Clin Trials. 2014 Mar-Apr;15(2):51-6. doi: 10.1310/hct1502-51.

PMID:
24710918
[PubMed - indexed for MEDLINE]
7.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team.

Lancet. 2012 Jun 30;379(9835):2439-48. doi: 10.1016/S0140-6736(12)60917-9. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

PMID:
22748591
[PubMed - indexed for MEDLINE]
8.

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.

Song I, Min SS, Borland J, Lou Y, Chen S, Ishibashi T, Wajima T, Piscitelli SC.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):365-7. doi: 10.1097/QAI.0b013e3181e67909.

PMID:
20585260
[PubMed - indexed for MEDLINE]
9.

Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

Schrijvers R, Debyser Z.

Expert Opin Pharmacother. 2012 Sep;13(13):1969-83. doi: 10.1517/14656566.2012.712514. Epub 2012 Jul 31. Review.

PMID:
22849516
[PubMed - indexed for MEDLINE]
10.

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.

Olin JL, Spooner LM, Klibanov OM.

Ann Pharmacother. 2012 Dec;46(12):1671-7. doi: 10.1345/aph.1R468. Epub 2012 Nov 7. Review.

PMID:
23136357
[PubMed - indexed for MEDLINE]
11.

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.

Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J; GS-236-0103 Study Team.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):483-6. doi: 10.1097/QAI.0b013e318286415c.

PMID:
23337366
[PubMed - indexed for MEDLINE]
12.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.

Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):163-70. doi: 10.1111/j.1742-7843.2010.00636.x. Epub 2010 Oct 27.

PMID:
20977679
[PubMed - indexed for MEDLINE]
13.

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.

Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J; GS-US-236-0102 Study Team.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100. doi: 10.1097/QAI.0b013e318289545c.

PMID:
23392460
[PubMed - indexed for MEDLINE]
14.

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.

J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.

PMID:
19776037
[PubMed - indexed for MEDLINE]
Free Article
15.

Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.

TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.

AIDS. 2009 Apr 27;23(7):825-33. doi: 10.1097/QAD.0b013e32832949d5.

PMID:
19307941
[PubMed - indexed for MEDLINE]
16.

Emtricitabine/tenofovir disoproxil fumarate.

[No authors listed]

Drugs R D. 2004;5(3):160-1. Review.

PMID:
15139777
[PubMed - indexed for MEDLINE]
17.

HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.

Andreatta K, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):367-74. doi: 10.1097/QAI.0b013e31827b55f1.

PMID:
23187937
[PubMed - indexed for MEDLINE]
18.

Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.

Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE; COL104422 Study Team.

HIV Med. 2010 Mar;11(3):193-9. doi: 10.1111/j.1468-1293.2009.00765.x. Epub 2009 Oct 23.

PMID:
19863619
[PubMed - indexed for MEDLINE]
19.

A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.

De Clercq E.

Expert Opin Pharmacother. 2009 Dec;10(17):2935-7. doi: 10.1517/14656560903418467.

PMID:
19929712
[PubMed - indexed for MEDLINE]
20.

Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.

Muñoz de Benito RM, Arribas López JR.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):523-35. Review.

PMID:
17009933
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk